Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors

In the latest trading session, Adma Biologics (ADMA) closed at $8.69, marking a +1.4% move from the previous day. The stock's change was more than the S&P 500's daily loss of 1.44%. Elsewhere, the Dow saw a downswing of 0.09%, while the tech-heavy Nasdaq depreciated by 2.22%. Prior to today's trading, shares of the infectious disease drug developer had gained 4% outpaced the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.The upcoming earnings release of Adma Biologics will be of great interest to investors. In that report, analysts expect Adma Biologics to post earnings of $0.16 per share. This would mark year-over-year growth of 6.67%. Meanwhile, our latest consensus estimate is calling for revenue of $125.77 million, up 3.11% from the prior-year quarter. For the full year, the Zacks Consensus Estimates project earnings of $0.82 per share and a revenue of $535 million, demonstrating changes of +36.67% and +4.87%, respectively, from the preceding year. It is also important to note the recent changes to analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 2.38% decrease. Adma Biologics is holding a Zacks Rank of #5 (Strong Sell) right now. In terms of valuation, Adma Biologics is currently trading at a Forward P/E ratio of 10.45. This signifies a discount in comparison to the average Forward P/E of 21.4 for its industry. The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 156, positioning it in the bottom 37% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks